Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Argus opinion
View:
Post by milafeijo on Apr 19, 2022 6:18pm

Argus opinion

https://www.prnewswire.com/news-releases/argus-research-initiates-equity-report-coverage-on-promis-neurosciences-inc-tsxpmn--otcqb-arfxf-301526823.html
Comment by FarmerBetty on Apr 19, 2022 7:11pm
What a joke, look back at the last NewYork company that covered them for years ?
Comment by bball67 on Apr 20, 2022 8:14am
Farmer, not happy with the crop you planted? Your anger, bitterness and negativity towards Promis is overwhelming. 
Comment by FarmerBetty on Apr 20, 2022 8:27am
Not bitterness, just the truth, after a number of years recycling the same old.  At this point you have to call it as it is? A fraud with Elliote the consultant and Eugene.
Comment by bball67 on Apr 20, 2022 8:42am
Plow the crop under that you planted, sell it. Move on. You do have a bitterness towards two individuals at Promis and can't let it go. 
Comment by FarmerBetty on Apr 20, 2022 8:57am
The truth hurts?
Comment by M101 on Apr 20, 2022 3:06pm
It does indeed. Face it, independent retail investors are just dirt to the role models of our consultants. https://endpts.com/gsk-manufacturing-workers-vote-to-strike-over-pay-dispute-as-walmsley-promises-company-growth/
Comment by M101 on Apr 20, 2022 12:45pm
These investment research sites offer a service but what's the value when the sites are ubiquitous and your promotion disappears within a few days? Pretend you're a potential investor looking for small cap cutting edge biotech stocks and see Argus meets your search need. That functionality isn't there, so this is just an "investment" in cognitive dissonance for current ...more  
Comment by FarmerBetty on Apr 20, 2022 8:14pm
Second VP from Pfizer, less qualified in my opinon than James Kupeic the former chief medical officer of Promis a former VP at Pfizer.  James now a Chief Clinical Medical Officer at Cassava sciences in clinical trials. In hot water with a class action law suit announced recently.
Comment by azzymaa on Apr 21, 2022 12:49am
Betty is on Fire! 
Comment by Gbathat on Apr 21, 2022 7:34am
Great to see another critical milestone nearing completion. .  "[PMN is] preparing GLP toxicology and pharmacokinetics (PK) studies in nonhuman primates. ProMIS expects to complete the PK studies during the second quarter of 2022."
Comment by bball67 on Apr 21, 2022 1:46pm
Farmer, you sure are spreading alot of cow manure lately. Can we get you out of your grumpy mood. Is monkey testing better than testing "rats" (actually mice)? Lets say the nonhuman primate testing of PMN 310, in the April-June 2022 timeframe, produces some incredible therapeutic results. Lets say that dosing is tested from small dosages to 20X that dosage. Lets say that side effects at ...more  
Comment by azzymaa on Apr 21, 2022 2:39pm
I sold at 0.125 and evened out. I bought back the same amount at .011. Back in the game! 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities